Provention Bio (PRVB +1.1%) announced the initiation of the Phase 2b PROACTIVE study of PRV-015, an anti-interleukin-15 monoclonal antibody, in adult celiac patients not responding to a gluten-free diet, a condition known as ‘Non-Responsive Celiac Disease‘.
Provention is developing PRV-015 under its 2018 collaboration with Amgen.
“PRV-015 has the potential to be the first-ever approved therapeutic for celiac disease.” stated Francisco Leon, MD, PhD, Chief Scientific Officer and Co-Founder.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.